Catalyst Pharmaceuticals Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Catalyst Pharmaceuticals's estimated annual revenue is currently $5.2M per year.
- Catalyst Pharmaceuticals received $57.5M in venture funding in November 2017.
- Catalyst Pharmaceuticals's estimated revenue per employee is $76,853
- Catalyst Pharmaceuticals's total funding is $15.1M.
- Catalyst Pharmaceuticals has 68 Employees.
- Catalyst Pharmaceuticals grew their employee count by 48% last year.
- Catalyst Pharmaceuticals currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
What Is Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette's Disorder. Catalyst's lead candidate, Firdapse® for the treatment of LEMS, has completed testing in a global, multi-center, double-blinded randomized pivotal Phase 3 trial resulting in positive top-line data and Catalyst has recently filed an NDA for this product seeking approval for its use as a treatment of LEMS and CMS. Firdapse® for the treatment of LEMS has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and orphan drug designation for LEMS and CMS. Firdapse® is the first and only European approved drug for symptomatic treatment in adults with LEMS. Catalyst is also developing CPP-115 to treat infantile spasms, epilepsy and other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette's Disorder. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission. In addition, Catalyst is developing a generic version of Sabril® (vigabatrin).keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Adriana Manari||Manager, Clinical Trial||Email Available|
|Dan Brennan||Chief Commercial Officer||Email Available|
|David Caponera||VP Patient Engagement & Access Support||Email Available|
|Isabel Nunez||Executive Assistant To Chief Executive Officer||Email Available|
|Ismaris Bouchard||Director Of Financial Reporting||Email Available|
|Jeff Gilbert||Regional Account Manager||Email Available|
|Desiree Hollandsworth||Director, Marketing And Commercial Operations|
|Amy Grover||Director of Patient Advocacy||Email Available|
|Kay Forshee||Director of Revenue Management||Email Available|
|Brian Elsbernd||Chief Legal And Compliance Officer||Email Available|
Catalyst Pharmaceuticals News
Intraday Trading of Catalyst Pharmaceuticals, Inc.: If one intends to pursue a career as a trader, then one must understand and choose between ...
CORAL GABLES, Fla., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical ...
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)'s share price reached a new 52-week high on Friday . The stock traded as high as $6.69 and ...
Catalyst Pharmaceuticals Funding
|2012-05-31||$4.0M||Undisclosed||Cowen and Company LLC||Article|
|2012-08-29||$6.0M||Undisclosed||Roth Capital Partners||Article|
|2014-04-09||$26.8M||Undisclosed||Piper Jaffray & Co||Article|
|2015-02-10||$34.7M||Undisclosed||Piper Jaffray & Co||Article|
|2017-11-29||$57.5M||Undisclosed||Piper Jaffray & Co||Article|
Catalyst Pharmaceuticals Executive Hires
|2006-09-08||Charles W. Gorodetzky||CMO||Article|
|2007-04-05||Steven R. Miller||VP Pharmaceutical Development||Article|
|2008-03-06||Patrick Kenny||Dir Corporate Clinical Compliance||Article|
|2009-10-14||Steven R. Miller||Chief Scientific Officer||Article|
|2011-11-15||Richard P. Rieger||VP Commercial Operations||Article|
|2013-03-06||Bernardino Mosquera||VP Clinical Operations||Article|
|2014-09-05||David D. Muth||EVP Corporate Development||Article|
|2014-10-29||David J. Caponera||VP Patient Advocacy and Reimbursement||Article|
|2015-01-06||David D. Muth||EVP/Chief Commercial Officer||Article|
|2016-02-29||Brian Elsbernd||SVP Legal & Compliance||Article|
|2018-06-14||Daniel Brennan||Chief Commercial Officer||Article|
|2018-08-07||Jason James||svp Commercial Operations & Analytics||Article|
|2018-08-21||Stanley Iyadurai||VP Clinical Development||Article|